News round-up for 3-7 March by DDW Senior Digital Content Editor Diana Spencer.

Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery.

The top stories:

Start-up takes a new approach to targeted protein degradation

Argobio and the Institut Pasteur have launched Enodia Therapeutics, a French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections.

Read more…

Scottish biotech company secures £3.4m investment

uFraction8 has secured £3.4 ($4.2) million in new investment following the completion of a funding round led by Foresight Group.

Read more…

First cell therapy company lists on the Oslo Stock Exchange

Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.

Read more…

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.

Read more…

Start-up harnesses protein degradation for neurodegenerative diseases

TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round.

Read more…